cfh-protein

CFH Protein — Complement Factor H

Complement Factor H (CFH) is the principal soluble regulator of the alternative pathway of the complement system, a critical component of the innate immune system[@ricklin2010]. As a 155 kDa glycoprotein composed of 20 short consensus repeat (SCR) domains, CFH plays an essential role in distinguishing self from non-self tissues by preventing complement-mediated damage to host cells while facilitating the clearance of pathogens and cellular debris. Beyond its well-established role in age-related macular degeneration (AMD)[@klein2005], emerging research demonstrates that CFH and the complement system more broadly participate in neuroinflammation, synaptic pruning, and microglial activation���all processes central to neurodegenerative disease pathogenesis[@veerhuis2011].

CFH Protein — Complement Factor H

Complement Factor H (CFH) is the principal soluble regulator of the alternative pathway of the complement system, a critical component of the innate immune system[@ricklin2010]. As a 155 kDa glycoprotein composed of 20 short consensus repeat (SCR) domains, CFH plays an essential role in distinguishing self from non-self tissues by preventing complement-mediated damage to host cells while facilitating the clearance of pathogens and cellular debris. Beyond its well-established role in age-related macular degeneration (AMD)[@klein2005], emerging research demonstrates that CFH and the complement system more broadly participate in neuroinflammation, synaptic pruning, and microglial activation���all processes central to neurodegenerative disease pathogenesis[@veerhuis2011].

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CFH Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Complement Factor H</td></tr>
<tr><td><strong>Gene</strong></td><td>[CFH](/genes/cfh)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P08603](https://www.uniprot.org/uniprot/P08603)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>3rzw, 4b80, 5o39</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>155 kDa</td></tr>
<tr><td><strong>Length</strong></td><td>1,211 amino acids</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Plasma, Extracellular space</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Regulators of complement activation</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">52 edges</a></td>
</tr>
</table>
</div>

Overview

CFH acts as the primary regulator of the alternative pathway of complement activation, functioning to:

• Cofactor for factor I-mediated C3b cleavage: CFH serves as a cofactor for factor I to cleave C3b, preventing excessive complement amplification
• Decay-accelerating activity: CFH accelerates the decay of the alternative pathway C3 convertase (C3bBb), limiting complement deposition
• Host cell protection: CFH binds to host cell surfaces via glycosaminoglycans, protecting self-tissues from complement attack
• Fluid-phase regulation: CFH circulates at high concentrations (0.3-0.5 mg/mL) to regulate spontaneous C3 activation in plasma

Structure

Factor H is a 1,211-amino acid glycoprotein (approximately 155 kDa) composed of 20 short consensus repeats (SCRs, also called complement control protein modules or CCP modules), each approximately 60 amino acids in length, connected by short linker peptides[@morris2013].

Domain Organization

| Domain | Amino Acids | Function |
|--------|-------------|----------|
| SCR1-4 | 1-240 | Primary C3b binding site; cofactor activity |
| SCR5-8 | 241-480 | Heparin and C3d binding; cell surface recognition |
| SCR9-15 | 481-900 | Additional C3b binding; regulatory activity |
| SCR16-18 | 901-1080 | Dimerization interface; self-protection |
| SCR19-20 | 1081-1211 | Surface recognition; anchor to host cell membranes |

The elongated, flexible structure allows CFH to simultaneously interact with multiple complement components and cell surface glycans. Each SCR domain contains four conserved cysteine residues forming two disulfide bonds that stabilize the fold. The flexibility between SCR domains enables CFH to adopt various conformations for substrate recognition[@yang2013].

CFH Polymorphisms and Risk Variants

The CFH gene contains several polymorphisms associated with increased disease risk:

• Y402H (Tyr402His): Strong association with AMD; affects heparin and C-reactive protein binding
• V62I: Decreased risk of AMD
• D936E: Associated with altered complement regulation
• R1210C: Linked to atypical hemolytic uremic syndrome (aHUS)

Normal Function

Factor H is the primary soluble regulator of the alternative pathway of complement activation, functioning through multiple mechanisms[@singhroute2012]:

1. Cofactor Activity

2. Decay-Accelerating Activity

3. Host Cell Protection

4. Fluid-Phase Regulation

Role in Neurodegenerative Disease

Alzheimer's Disease

In Alzheimer's disease, complement activation and CFH play complex roles in amyloid-β plaque pathology and neuroinflammation[@stancu2014]:

Aβ and Complement Interaction: Amyloid-β (Aβ) peptides can directly activate the alternative pathway of complement, generating C3a and C5a anaphylatoxins that recruit and activate microglia. CFH normally limits this activation, but CFH can be recruited to Aβ plaques via its amyloid-binding properties.

CFH in Plaques: Immunohistochemical studies demonstrate CFH and other complement proteins co-localize with amyloid plaques in AD brain[@veerhuis2011]. CFH may attempt to limit complement-mediated inflammation but becomes overwhelmed or dysfunctional.

Genetic Association: CFH polymorphisms, particularly Y402H, have been investigated in AD risk, with some studies suggesting modest associations with disease onset or severity. The Y402H variant shows altered binding to Aβ and inflammatory mediators[@shi2021].

Microglial Activation: The complement system, including CFH-regulated pathways, influences microglial phenotypic activation. C1q and C3b opsonize synapses for elimination by microglia. CFH regulates this process by controlling C3b deposition and activation.

Parkinson's Disease

Complement activation occurs in the substantia nigra of PD patients, with evidence of altered complement regulation[@bonotis2016]:

• C3d Deposition: Complement activation products (C3d) are deposited on dopaminergic neurons
• CFH Expression: Altered CFH expression in the substantia nigra pars compacta
• Microglial Activation: Complement receptors mediate microglial phagocytosis of dying neurons

Amyotrophic Lateral Sclerosis (ALS)

Complement activation contributes to motor neuron injury in ALS[@zhou2020]:

• C1q Accumulation: C1q localizes to motor neurons in ALS spinal cord
• C3 Activation: Elevated C3b and iC3b in cerebrospinal fluid
• CFH Dysregulation: Altered CFH levels in ALS patients

Multiple Sclerosis

In multiple sclerosis, complement contributes to demyelination and oligodendrocyte loss[@zipp2010]:

• Oligodendrocyte Vulnerability: Complement-mediated cytotoxicity against oligodendrocytes
• Lesion Activity: CFH expression in active MS lesions
• Remyelination Failure: Incomplete complement regulation may impair repair

Normal Brain Function

Complement proteins including CFH participate in normal brain physiology:

Synaptic Pruning: During development, complement C1q and C3 tag synapses for elimination by microglia. CFH regulates this process to ensure appropriate pruning[@song2020].

Microglial Education: Complement components guide microglial synaptic surveillance and response to injury[@wood2022].

Therapeutic Targeting

Multiple therapeutic strategies targeting complement in neurodegenerative diseases are under development[@jiang2022]:

Approved Complement Inhibitors

| Drug | Target | Approval Status | Potential CNS Use |
|------|-------|----------------|-------------------|
| Eculizumab | C5 | PNH, aHUS | Investigational |
| Ravulizumab | C5 | PNH, aHUS | Investigational |
| Avacopan | C5aR1 | ANCA vasculitis | Investigational |

Investigational Approaches

• Factor H agonists: Enhance CFH function to reduce complement-mediated inflammation
• C1q inhibitors: Block complement initiation at synapses
• C3 inhibitors: Broader complement blockade (e.g., pegcetacoplan)
• Microglial modulation: Targeting complement receptors on microglia

Challenges for CNS Targeting

• Complement inhibition increases infection risk
• Blood-brain barrier limits CNS drug delivery
• Balancing complement's protective vs. pathological functions

Molecular Pathways

style A fill:#0a1929
style D fill:#3b1114
style F fill:#3b1114
style H fill:#3b1114
style G fill:#0e2e10
style I fill:#0e2e10

See Also

• [CFH Gene](/genes/cfh) — Gene encoding Complement Factor H
• [Complement System](/mechanisms/complement-system) — Overview of complement activation
• [Alzheimer's Disease](/diseases/alzheimers-disease) — AD and complement
• [Parkinson's Disease](/diseases/parkinsons-disease) — PD and complement
• [Microglia](/cell-types/microglia) — CNS immune cells
• [Neuroinflammation](/mechanisms/neuroinflammation) — Inflammatory processes in neurodegeneration
• [Synaptic Pruning](/mechanisms/synaptic-pruning) — Complement-mediated development

External Links

• [UniProt: P08603](https://www.uniprot.org/uniprot/P08603)
• [GeneCards: CFH](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CFH)
• [NCBI Gene: CFH](https://www.ncbi.nlm.nih.gov/gene/3070)
• [OMIM: CFH](https://www.omim.org/entry/134370)